NASDAQ:MXCT

MaxCyte (MXCT) Stock Price, News & Analysis

MaxCyte logo
$1.25 +0.08 (+6.84%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$1.36 +0.11 (+8.80%)
As of 05:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About MaxCyte Stock (NASDAQ:MXCT)

Advanced

Key Stats

Today's Range
$1.14
▼
$1.26
50-Day Range
$0.96
▼
$1.73
52-Week Range
$0.64
▼
$1.81
Volume
975,795 shs
Average Volume
1.47 million shs
Market Capitalization
$129.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Hold

Company Overview

MaxCyte, Inc. develops and commercializes cell-engineering technology used by biotechnology and pharmaceutical companies, academic research institutions, and cell therapy developers. Its platform is designed to introduce molecules such as DNA, RNA, and proteins into cells while maintaining cell viability, supporting applications in cell therapy, gene editing, and drug discovery.

The company’s offerings include its Flow Electroporation systems, related consumables, and services. MaxCyte also works with cell therapy developers through licensing agreements that allow them to use its technology in developing and manufacturing therapeutic products.

Founded in 1998 and headquartered in Rockville, Maryland, MaxCyte serves customers and partners internationally. Its technology is used across research and clinical development, as well as in the production of cell-based medicines.

AI Generated. May Contain Errors.

MaxCyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

MXCT MarketRank™: 
3.503084304315 of 5 stars

MaxCyte scored higher than 70% of companies evaluated by MarketBeat, and ranked 467th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MaxCyte has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    MaxCyte has a consensus price target of $4.50, representing about 260.0% upside from its current price of $1.25.

  • Amount of Analyst Coverage

    MaxCyte has only been the subject of 2 research reports in the past 90 days.

  • Read more about MaxCyte's stock forecast and price target.
  • Earnings Growth

    Earnings for MaxCyte are expected to grow in the coming year, from ($0.24) to ($0.17) per share.

  • Price to Book Value per Share Ratio

    MaxCyte has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.60% of the float of MaxCyte has been sold short.
  • Short Interest Ratio / Days to Cover

    MaxCyte has a short interest ratio ("days to cover") of 1.34, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MaxCyte has recently decreased by 13.57%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    MaxCyte does not currently pay a dividend.

  • Dividend Growth

    MaxCyte does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 2 news articles for MaxCyte this week, compared to 1 article on an average week.
  • MarketBeat Follows

    Only 1 people have added MaxCyte to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $121,000.00 in company stock, which represents 0.0938% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, MaxCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $121,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    4.10% of the stock of MaxCyte is held by insiders.

  • Percentage Held by Institutions

    68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MaxCyte's insider trading history.
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MXCT Stock News Headlines

MaxCyte (MXCT) Q3 2026 Earnings Call Transcript
A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
MaxCyte (MXCT) Expected to Release Quarterly Earnings on Tuesday
See More Headlines

MXCT Stock Analysis - Frequently Asked Questions

MaxCyte's stock was trading at $1.55 on January 1st, 2026. Since then, MXCT shares have decreased by 19.4% and is now trading at $1.25.

MaxCyte, Inc. (NASDAQ:MXCT) announced its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03. The firm earned $8.16 million during the quarter, compared to analysts' expectations of $7.39 million. MaxCyte had a negative trailing twelve-month return on equity of 15.05% and a negative net margin of 81.40%.
Read the conference call transcript
.

MaxCyte (MXCT) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.

Top institutional investors of MaxCyte include Liontrust Investment Partners LLP (4.69%), Brooklands Fund Management Ltd (1.52%), Marshall Wace LLP (1.51%) and Goldman Sachs Group Inc. (0.89%). Insiders that own company stock include Maher Masoud, Stanley C Erck, Douglas Doerfler, Douglas J Swirsky, William W Brooke, John Joseph Johnston, David I Sandoval, Ali Soleymannezhad, Rekha Hemrajani and Thomas M Ross.
View institutional ownership trends
.

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/10/2026
Today
11/18/2026
2026 Stephens Annual Investment Conference | NASH2026
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:MXCT
CIK
1287098
Employees
91
Year Founded
1998

Price Target and Rating

High Price Target
$5.00
Low Price Target
$4.00
Potential Upside/Downside
+260.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$44.63 million
Net Margins
-81.40%
Pretax Margin
-81.40%
Return on Equity
-15.05%
Return on Assets
-12.79%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.83
Quick Ratio
7.37

Sales & Book Value

Annual Sales
$33.03 million
Price / Sales
3.91
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.46 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
103,250,000
Free Float
99,017,000
Market Cap
$129.06 million
Optionable
Optionable
Beta
1.49

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:MXCT) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners